Novel Assay for Rapid Antibody Screening

描述（由申请人提供）：Primorigen Biosciences将使用I期SBIR资金开发一种无框架、多重、微阵列筛选系统，用于快速鉴定和表征对靶蛋白具有适当亲和力和特异性的抗体匹配对。该系统产生改进的测定内容，并显着降低了多重微阵列开发的时间和成本。这个新系统的核心是Primorigen的新型无框架微阵列装置，用于多重分析，允许直接在平面阵列表面上针对几个结合靶点测试96（或384）个样品。因此，可以高精度地检测数百个样品中的数十种蛋白质，每次实验生成数千个数据点，提高了筛选速度。虽然新系统可以适用于检测任何蛋白质，但该I期项目将专注于检测人类胰腺β细胞标志物，用于表征可能治疗或治愈1型糖尿病的胰岛素分泌细胞系。第一阶段项目将开发无框架硝酸纤维素测定表面，并使用微型阵列方法来筛选和表征检测目标蛋白的抗体。第II阶段将a）验证这些检测试剂盒的商业用途，B）开发生产方案，以及c）将该系统应用于细胞分化标志物。

DESCRIPTION (provided by applicant): Primorigen Biosciences will use Phase I SBIR funds to develop a frameless, multiplexed, microarray screening system for rapid identification and characterization of antibody matched pairs with appropriate affinity and specificity for target proteins. This system produces improved assay content and dramatically reduces the time and cost of multiplexed microarray development. The core of this new system is Primorigen's novel frameless microarray device for multiplexed analysis that allows testing of 96 (or 384) samples against several binding targets directly on a flat array surface. As a result, dozens of proteins in hundreds of samples can be detected with high precision to generate thousands of data points per experiment, increasing speed of screening. While the new system can be adapted to detect any protein, this Phase I project will focus on detecting human pancreatic beta cell markers useful for characterizing insulin-secreting cell lines that may be candidates to treat or cure Type 1 diabetes. The Phase I project will develop a frameless nitrocellulose assay surface and use the miniaturized array methods to screen and characterize antibodies that detect the target proteins. Phase II will a) validate these assays for commercial use, b) develop manufacturing protocols, and c) apply this system to cell differentiation markers.